



DIAGNOS

Your Knowledge Partner

PRESS RELEASE

OTCQB: DGNOF
TSXV: ADK
SOURCE: DIAGNOS Inc.

2018.07.10

DIAGNOS Installs its First Retina Screening Clinic based on Artificial Intelligence in Panama

Brossard, Quebec, Canada – July 10, 2018 - Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today the installation of its first retina AI screening clinic, in the Panama’s private health sector.

“We are delighted to open our first of 15 Medical clinics in Panama in collaboration with DIAGNOS”, said the CEO and owner of these clinics. He also added: “We encourage and support DIAGNOS in its endeavor as an AI pioneer in the early detection of critical health issues, such as diabetic retinopathy. We are also looking forward to the upcoming release of the hypertension application.”

“We are looking forward to a long term relationship with our new customer in Panama. We have been working with their team to establish a marketing strategy to support their growth objectives. We are anticipating a substantial growth in the number of patients to screen”, said Guillermo Moreno, Vice-President at DIAGNOS.

About DIAGNOS

DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (“POC”). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.

Additional information about DIAGNOS is available at www.diagnos.com and www.sedar.com.

For further information, please contact:

André Larente, President
DIAGNOS Inc.
Tél. : 450 678-8882, poste 224
alarente@diagnos.ca

Josh Falle
Momentum PR
Tel: 514-416-4656
josh@momentumpr.com



DIAGNOS

Your Knowledge Partner

PRESS RELEASE

OTCQB: DGNOF
TSXV : ADK
SOURCE : DIAGNOS Inc.

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.